Nurix

Nurix Therapeutics aims to change the way disease is treated using degrader-based medicines, harnessing the cell's natural protein degradation machinery, the ubiquitin-proteasome system. Founded on groundbreaking research from UC Berkeley and UC San Francisco, Nurix started as an E3 ligase-centric company. Its proprietary DEL-AI discovery engine integrates in-house DNA Encoded Libraries, a collection of ligase binders, automated chemistry and direct-to-biology capabilities, with machine learning. The company is advancing a multi-modal pipeline targeting diseases in oncology, immunology, and neurology, and has forged strategic alliances with industry leaders like Roche, Gilead Sciences, Sanofi, and Pfizer.

Nurix Therapeutics aims to fundamentally change the way disease is treated using degrader-based medicines. Its journey began with a vision to harness the power of the cell's natural protein degradation machinery, the ubiquitin-proteasome system, to create a new class of therapeutics that can overcome the limitations of current treatments. Founded on groundbreaking research from UC Berkeley and UC San Francisco, Nurix started as an E3 ligase-centric company, with deep understanding of E3 ligase biochemistry, structure, and biological activity laying the foundation for its approach to drug discovery and development. At the heart of its innovation is the proprietary DEL-AI discovery engine, which integrates in-house DNA Encoded Libraries (DEL), an expansive collection of ligase binders, and automated chemistry and direct-to-biology capabilities, with novel insights from the application of machine learning. Nurix has evolved into a targeted protein degradation powerhouse and has forged strategic alliances with industry leaders like Roche, Gilead Sciences, Sanofi, and Pfizer.

Establishing degrader-based medicines at the forefront of patient care

• Degraders

  Designed to eliminate disease-causing proteins by harnessing the cell's natural protein degradation machinery.

• Degrader-Antibody Conjugates (DACs)

  Combine the cell specificity of antibodies with the potency, selectivity, and catalytic activity of degraders, delivering innovative medicines with the potential for enhanced precision and improved safety.

• DEL-AI drug discovery engine

  Integrates in-house DNA Encoded Libraries (DEL), an expansive collection of ligase binders, and automated chemistry and direct-to-biology capabilities, with novel insights from the application of machine learning.

1. 1Nurix | Medicines to Outmatch Diseasenurixtx.com
2. 2Writing Medicine's Next Chapternurixtx.com
3. 3Learn About Us | Nurixnurixtx.com
4. 4Nurix (United States)wikidata.org